Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia®) in tumour-bearing dogs: A phase I dose-finding study

Veterinary and Comparative Oncology

Volumn 14, Issue 2, 2016, Pages 202-209

  Pan, X ^a   Tsimbas, K ^a   Kurzman, I D ^a   Vail, D M ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Canine; CCNU; Chemotherapy; Toceranib; Tyrosine kinase

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG COMBINATION; INDOLE DERIVATIVE; LOMUSTINE; PYRROLE DERIVATIVE; TOCERANIB;

ANIMAL; CLINICAL TRIAL; DOG; DOG DISEASES; DOSE RESPONSE; DRUG COMBINATION; NEOPLASMS; PHASE 1 CLINICAL TRIAL; VETERINARY;

ANIMALS; ANTINEOPLASTIC AGENTS; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; INDOLES; LOMUSTINE; NEOPLASMS; PYRROLES;

EID: 84899039261     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/vco.12091     Document Type: Article

References (34)

1. Liao AT, Chien MB, Shenoy N, Mendel DB, McMahon G, Cherrington JM and London CA. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 2002; 100: 585-593. doi:10.1182/blood-2001-12-0350.
2. London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB, McMahon G and Cherrington JM. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clinical Cancer Research 2003; 9: 2755-2768.
3. Lemmon MA and Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141: 1117-1134. doi:10.1016/j.cell.2010.06.011.
4. Millanta F, Caneschi V, Ressel L, Citi S and Poli A. Expression of vascular endothelial growth factor in canine inflammatory and non-inflammatory mammary carcinoma. Journal of Comparative Pathology 2010; 142: 36-42. doi:10.1016/j.jcpa.2009.06.004.
5. Maiolino P, De Vico G and Restucci B. Expression of vascular endothelial growth factor in basal cell tumours and in squamous cell carcinomas of canine skin. Journal of Comparative Pathology 2000; 123: 141-145. doi:10.1053/jcpa.2000.0404.
6. Restucci B, Papparella S, Maiolino P and De Vico G. Expression of vascular endothelial growth factor in canine mammary tumors. Veterinary Pathology 2002; 39: 488-493.
7. Millanta F, Silvestri G, Vaselli C, Citi S, Pisani G, Lorenzi D and Poli A. The role of vascular endothelial growth factor and its receptor Flk-1/KDR in promoting tumour angiogenesis in feline and canine mammary carcinomas: a preliminary study of autocrine and paracrine loops. Research in Veterinary Science 2006; 81: 350-357. doi:10.1016/j.rvsc.2006.01.007.
8. Shiomitsu K, Johnson CL, Malarkey DE, Pruitt AF and Thrall DE. Expression of epidermal growth factor receptor and vascular endothelial growth factor in malignant canine epithelial nasal tumours. Veterinary and Comparative Oncology 2009; 7: 106-114. doi:10.1111/j.1476-5829.2009.00178.x.
9. Al-Dissi AN, Haines DM, Singh B and Kidney BA. Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor associated with tumor cell proliferation in canine cutaneous squamous cell carcinomas and trichoepitheliomas. Veterinary Pathology 2007; 44: 823-830. doi:10.1354/vp.44-6-823.
10. Yonemaru K, Sakai H, Murakami M, Yanai T and Masegi T. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and their receptors (flt-1, flk-1, and flg-1) in canine vascular tumors. Veterinary Pathology 2006; 43: 971-980. doi:10.1354/vp.43-6-971.
11. Platt SR, Scase TJ, Adams V, Wieczorek L, Miller J, Adamo F and Long S. Vascular endothelial growth factor expression in canine intracranial meningiomas and association with patient survival. Journal of Veterinary Internal Medicine 2006; 20: 663-668.
12. Rebuzzi L, Willmann M, Sonneck K, Gleixner KV, Florian S, Kondo R, Mayerhofer M, Vales A, Gruze A, Pickl WF, Thalhammer JG and Valent P. Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Veterinary Immunology and Immunopathology 2007; 115: 320-333. doi:10.1016/j.vetimm.2006.11.009.
13. Al-Dissi AN, Haines DM, Singh B and Kidney BA. Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor in canine cutaneous fibrosarcomas. Journal of Comparative Pathology 2009; 141: 229-236. doi:10.1016/j.jcpa.2009.05.004.
14. London C, Mathie T, Stingle N, Clifford C, Haney S, Klein MK, Beaver L, Vickery K, Vail DM, Hershey B, Ettinger S, Vaughan A, Alvarez F, Hillman L, Kiselow M, Thamm D, Higginbotham ML, Gauthier M, Krick E, Phillips B, LaDue T, Jones P, Bryan J, Gill V, Novasad A, Fulton L, Carreras J, McNeill C, Henry C and Gillings S. Preliminary evidence for biologic activity of toceranib phosphate (Palladia((R))) in solid tumours. Veterinary and Comparative Oncology 2012; 10: 194-205. doi:10.1111/j.1476-5829.2011.00275.x.
15. Robat C, London C, Bunting L, McCartan L, Stingle N, Selting K, Kurzman I and Vail DM. Safety evaluation of combination vinblastine and toceranib phosphate (Palladia(R)) in dogs: a phase I dose-finding study(*). Vet Comp Oncol, 2011. doi:10.1111/j.1476-5829.2011.00261.x.
16. Chon E, McCartan L, Kubicek LN and Vail DM. Safety evaluation of combination toceranib phosphate (Palladia(R)) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study(*). Vet Comp Oncol, 2011. doi:10.1111/j.1476-5829.2011.00265.x.
17. Rassnick KM, Bailey DB, Russell DS, Flory AB, Kiselow MA, Intile JL, Malone EK, Balkman CE and Barnard SM. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours. Veterinary and Comparative Oncology 2010; 8: 138-152. doi:10.1111/j.1476-5829.2010.00217.x.
18. Rassnick KM, Moore AS, Russell DS, Northrup NC, Kristal O, Bailey DB, Flory AB, Kiselow MA and Intile JL. Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma. Journal of Veterinary Internal Medicine 2010; 24: 1528-1531.
19. Saba CF, Thamm DH and Vail DM. Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma. Journal of Veterinary Internal Medicine 2007; 21: 127-132.
20. Williams LE, Rassnick KM, Power HT, Lana SE, Morrison-Collister KE, Hansen K and Johnson JL. CCNU in the treatment of canine epitheliotropic lymphoma. Journal of Veterinary Internal Medicine 2006; 20: 136-143.
21. Risbon RE, de Lorimier LP, Skorupski K, Burgess KE, Bergman PJ, Carreras J, Hahn K, Leblanc A, Turek M, Impellizeri J, Fred R III, Wojcieszyn JW, Drobatz K and Clifford CA. Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): a retrospective study of 46 cases (1999-2004). Journal of Veterinary Internal Medicine 2006; 20: 1389-1397.
22. Jung DI, Kim HJ, Park C, Kim JW, Kang BT, Lim CY, Park EH, Sur JH, Seo MH, Hahm DH and Park HM. Long-term chemotherapy with lomustine of intracranial meningioma occurring in a miniature schnauzer. The Journal of Veterinary Medical Science 2006; 68: 383-386.
23. Veterinary Co-operative Oncology Group. Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Veterinary and Comparative Oncology 2004 pii: VCO053b; 2: 195-213. doi:10.1111/j.1476-5810.2004.0053b.x.
24. Skorupski KA, Hammond GM, Irish AM, Kent MS, Guerrero TA, Rodriguez CO and Griffin DW. Prospective randomized clinical trial assessing the efficacy of Denamarin for prevention of CCNU-induced hepatopathy in tumor-bearing dogs. Journal of Veterinary Internal Medicine 2011; 25: 838-845. doi:10.1111/j.1939-1676.2011.0743.x.
25. Vail DM. Cancer clinical trials: development and implementation. The Veterinary Clinics of North America. Small Animal Practice 2007 pii: S0195-5616(07)00089-7; 37: 1033-1057. doi:10.1016/j.cvsm.2007.06.007.
26. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 2009; 45: 228-247. doi:10.1016/j.ejca.2008.10.026.
27. Vail DM, Michels GM, Khanna C, Selting KA, London CA and Veterinary Cooperative Oncology Group. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0) - a Veterinary Cooperative Oncology Group (VCOG) consensus document. Veterinary and Comparative Oncology 2010; 8: 28-37. doi:10.1111/j.1476-5829.2009.00200.x.
28. Bernabe LF, Portela R, Nguyen S, Kisseberth WC, Pennell M, Yancey MF and London CA. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose. BMC Veterinary Research 2013; 9: 190. doi:10.1186/1746-6148-9-190.
29. Robat C, London C, Bunting L, McCartan L, Stingle N, Selting K, Kurzman I and Vail DM. Safety evaluation of combination vinblastine and toceranib phosphate (Palladia(R)) in dogs: a phase I dose-finding study. Veterinary and Comparative Oncology 2012; 10: 174-183. doi:10.1111/j.1476-5829.2011.00261.x.
30. Scagliotti GV. Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer. Annals of Oncology 2007; 18(Suppl 10): x32-x41. doi:10.1093/annonc/mdm412.
31. Pujol JL, Viens P, Rebattu P, Laurie SA, Feld R, Deneulin A and Fandi A. Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patients. Journal of Thoracic Oncology 2006; 1: 417-424.
32. Yancey MF, Merritt DA, Lesman SP, Boucher JF and Michels GM. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors. Journal of Veterinary Pharmacology and Therapeutics 2010; 33: 162-171. doi:10.1111/j.1365-2885.2009.01133.x.
33. Yancey MF, Merritt DA, White JA, Marsh SA and Locuson CW. Distribution, metabolism, and excretion of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in dogs. Journal of Veterinary Pharmacology and Therapeutics 2010; 33: 154-161. doi:10.1111/j.1365-2885.2009.01120.x.
34. Chang TK, Chen H and Waxman DJ. 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) modulates rat liver microsomal cyclophosphamide and ifosphamide activation by suppressing cytochrome P450 2C11 messenger RNA levels. Drug Metabolism and Disposition 1994; 22: 673-679.